www.sutrobio.com

sutro biopharma, inc. is a public biotechnology company headquartered in south san francisco, california focused on clinical stage drug discovery, development and manufacturing company. using its integrated cell-free protein synthesis platform, xpresscf, to create a variety of protein therapeutics for cancer and autoimmune disorders. it focuses to design therapeutics using potent modalities, including cytokine based immune-oncology (i/o) therapeutics, antibody-drug conjugates (adcs) and bispecific antibodies that are directed primarily against clinically validated targets. its product candidates include stro-001 and stro-002. stro-001 is an adc directed against the cancer target cd74, for patients with multiple myeloma and non-hodgkin lymphoma (nhl). stro-002 is an adc directed against folate receptor-alpha (folra), for patients with ovarian and endometrial cancers. stro-001 and stro-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its xpresscf platform.